Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 4, 2010

Amplimmune Gets $23M Up Front from GSK to Develop PD-1-Targeting Drugs

  • Amplimmune will receive a $23 million up-front payment from GlaxoSmithKline (GSK) as part of a broad collaboration centered on developing PD-1-targeting therapeutics against cancer and other diseases. The agreement gives GSK exclusive, worldwide rights to AMP-224 and any new next-generation fusion proteins targeting PD-1. Amplimmune could receive up to $485 million in regulatory, development, and sales milestones plus sales royalties.

    GSK separately inked a deal with Five Prime focused on skeletal muscle disorders. The firm paid $15 million up front and additional fees of $124 million over and above research funding in 2011 and 2013.

    Amplimmune's AMP-224 is an Fc-fusion protein designed to block interaction between PD-1 and B7-H1 to overcome immune suppression and allow the immune system to fight cancer and chronic infections. Amplimmune says it expects to start Phase I trials with AMP-224 in cancer patients next year. The firm is also working to complete cGMP manufacturing and toxicology studies to support progression of AMP-224 into the clinic.

    The two partners will in addition work together to define the mechanism of action of AMP-224 and evaluate the fusion protein’s potential utility in oncology, infectious diseases, and vaccine applications. Excluding the Phase I trial with AMP-224, GSK will be responsible for all other development and manufacturing activities associated with product development.

    Amplimmune is focused on the development of immune-based biologics for treating cancer, autoimmunity, transplantation-related disorders, and infectious diseases. The firm’s platform, originally developed by its founders at Johns Hopkins University, centers on immunological checkpoint and co-stimulatory molecules as the basis for developing treatments that modulate critical mechanisms in the body's immune system. A mouse version of AMP-224 has already shown promising activity in mouse models of cancer and infectious disease, Amplimmune claims.

    In addition to AMP-224, the Amplimmune pipeline includes another preclinical-stage candidate, AMP-110, for the treatment of autoimmune diseases. AMP-110 targets T cells and is designed to elicit a co-inhibitory signal that suppresses T-cell responses.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »